SlideShare uma empresa Scribd logo
1 de 26
Baixar para ler offline
Role of GLP Compliance in
Generating Accurate & Reproducible
BE Data
Dr. Bhaswat S. Chakraborty
Sr. VP & Chair, R&D Core Committee
Cadila Pharmaceuticals Ltd.
Presented at ACRO India Workshop
AMA, Ahmedabad, India, July 19-20, 2013
1
Contents
• GLP, its evolution
• Fundamentals of GLP
– Resources
– Rules & Characterization
– Documentation & QAU
• Regulatory BE studies
• GLP in BE
– USFDA, EU
• Legal & Excellence GLP
• GLP expectations in Bioanalytical
• Best BE Results
• Concluding remarks
2
Good Laboratory Practices (GLP)
• Good Laboratory Practices or GLPs were initially invoked in a
reaction to malpractices in laboratories conducting safety
experiments of medicines.
• In early 1970s, research laboratories in the USA were found
doing work in unethical ways, like:
– data generation without conduct of study
– falsification of laboratory work
– replacement of dead animals and fabrication of test results etc.
• As a result, a series of guidelines were issued by US FDA,
Japan and finally by the whole group of OECD countries.
Board and Dent 19963
Evolution of GLP
• 1976 – USA: FDA proposals
• 1978 – USA: FDA final rules
• 1980 – USA : FDA amendment to GLP
• 1981 – OECD: Guidelines for testing of chemicals – OECD Paris and
Guidelines for National GLP inspections – Paris
• 1982 – OECD: GLP in testing of chemicals - Paris
• 1984 – Japan: GLP proposals and notification to agricultural
production bureau
• 1987 – USA: FDA amendment final rule
• 1988 – OECD: Final report for working group on mutual
recognition of compliance with GLP
• 1989 – UK: GLP compliance program
Board and Dent 19964
Fundamentals of GLP
1) Resources: organization, personnel, facilities
and equipment.
2) Rules: protocols and written procedures
(SOPs).
3) Characterization: test items and test systems.
4) Documentation: raw data, final report and
archives.
5) Quality assurance unit.
5
Resources
• Organization and Personnel:
– structure of the research organization and responsibilities of the
research personnel should be clearly defined
– staffing levels must be sufficient to perform the tasks required
– qualifications and the training of staff must also be defined and
documented
• Facilities and Equipment:
– sufficient facilities and equipment must be existent in order to
perform the studies
– all equipment must be in working order.
6
Rules & Characterization
• Protocols and Written Procedures:
– main steps of research studies must be described in the
study plan or protocol
– for repeatability of the studies and reproducibility of
results, routine procedures are described in SOPs
• Test item and the Test system
– essential to know as much as possible about the test item
and about the test system (often an animal or plant) to
which it is administered.
7
Documentation & QAU
• Raw data must be accurately captured and organized to
reflect the procedures and conditions of the study
• Final report is the responsibility of the study director,
ensuring
– that the contents, results and interpretation thereof are accurate
• Archives should be safe for many years and equipped with
logical and prompt retrieval.
 
• Quality assurance (QA) is a team assuring GLP compliance
– organized independently of the operational and study program, and
function as witnesses to the whole pre-clinical research process.
8
Critical GLP Violations
• Fabrication or falsification of data
• No Quality Assurance
• No study allotment
• No approved written study plans
• Failure to date, initial or sign data entries
• No training records and / or no job descriptions for
study personnel
• Absence of required information in final reports
9
Critical GCP Violations
• Fabrication or falsification of data
• Evidence that formal procedure/systems were not in place or rather weak
• Lack of/inadequate Quality Certification.
• Importation and mfg. of investigational product without regulatory licence
• Inaccurate information about investigational product is supplied to
regulatory agency
• Use of expired/recalled/non GMP manufactured investigational product
• Poor/ineffective blinding system
• Poor accountability of investigational product
• Poorly documented/incorrect sponsorship/Legal Representative
arrangements
• Uncontrolled site to site transfer
• Failure to observe IND conditions
• Failure to report serious breaches of trial protocol/GCP
• Little or no oversight of pharmacovigilance requirements
Regulatory Bioequivalence (BE)
Studies
• Clinical studies in healthy volunteers
– GCP compliance is a must
• Involves laboratory measurements of drug
concentrations in blood samples
– Logically GLP should be applicable
• They are not non-clinical, safety studies
– Thus may NOT have to CLAIM GLP compliance
11
Scope Demarcation: GCP and GLP
• GCP: relate to clinical studies using human volunteers patients and
also relate to most of the clinical procedures that can be carried out
without a laboratory test
– Includes all clinical phase I-IV studies
• GLP apply to all analytical and testing process all safety studies for
human health market approval and include QC assays, clinical
chemistry and tests by instruments and certain bioanalytical
procedures
– Excludes validation studies, cosmetic safety, bioanalytical for
efficacy studies including animal efficacy studies
• Good QA is applicable to all biomedical research practices
12
GLP in BE
• Common perceptions
– Confusing
– Only in the testing of non-clinical safety aspects
– Applies to bioanalytical? Or bioanalytical only?
– Wherever there is a lab
• Clinical pathology
• Serology
• Microbiology
• Bioanalytical…
13
Guidance for Industry,
USFDA/CDER, May 2001
• “The analytical laboratory conducting
pharmacology/toxicology and other preclinical
studies for regulatory submissions should adhere to
FDA’s Good Laboratory Practices (GLPs) (21 CFR part
58) and to sound principles of quality assurance
throughout the testing process.
• The bioanalytical method for human BA, BE, PK, and
drug interaction studies must meet the criteria in 21
CFR 320.29.”
14
21 CFR 320.29
• “….shall be demonstrated to be accurate and
of sufficient sensitivity to measure, with
appropriate precision, the actual
concentration of the active drug ingredient or
therapeutic moiety, or its active metabolite(s),
achieved in the body. ……”
15
EMEA CPMP/EWP/QWP/1401/98
• “The bioanalytical part of bioequivalence
trials should be performed in accordance
with the principles of Good Laboratory
Practice (GLP).
• However, as human bioanalytical studies fall
outside the scope of GLP, the sites conducting
the studies are not required to be monitored
as part of a national GLP compliance
programme.”
16
Bioanalytical Guidelines
EMEA/CHMP/EWP/192217/2009
• “The validation of bioanalytical methods and the analysis of
study samples should be performed in accordance with the
principles of Good Laboratory Practice (GLP).
• However, as human bioanalytical studies fall outside of the
scope of GLP, as defined in Directive 2004/10/EC, the sites
conducting the human studies are not required to be
monitored as part of a national GLP compliance programme.
• In addition, for clinical trials in humans the principles of Good
Clinical Practice (GCP) should be followed”.
17
18
Excellence vs Legal GLP
• Legal GLP
– Accredited
– Monitored & certified by authorities
• Excellence in GLP
– Protocol & study director
– Proper sample collection, storage and processing
– Validated calibration and QC
– Successful analysis of batches
– High quality data (QC)
– Excellent QA
• Tracing, accountability & accuracy
– Proper reporting
19
GLP expectations in Bioanalytical
• Pre-study method validation
– precision and accuracy – intra- and inter-batch across calibration
range, including LOQ
– selectivity – test for endogenous/exogenous interferences
– stability under study conditions – freeze/thaw, long-term frozen
storage, bench-top, auto-sampler (extract), stock solution
– recommend freshly prepared samples for comparison
– consider conditions of actual use – for example, increased batch size
during actual use
• Written, thorough documentation of the bioanalytical
method and results of validation
20Source: US FDA Guidelines & Presentations
GLP expectations in Bioanalytical..
• During incurred sample analysis
– select calibration range and QCs based on expected concentrations
for the study
– include a standard curve and quality control samples with each batch
of subject samples
– assure consistent integration of all chromatograms within a batch
• prepare complete study reports tabulate results for calibration standards,
QCs, subject samples
• list repeat results and the reason for the repeat
• list deviations and their impact
• description of failed runs
21Source: US FDA Guidelines & Presentations
GLP expectations in Bioanalytical...
• Reference standard – record identity, purity, expiration date,
lot number
• Document preparation – of stock solutions, and matrix-
based calibration standards and quality control (QC) samples
• Sample handling – store study samples under conditions that
maintain their integrity
• Document – storage condition, freezer removal/return
• Equipment – record instrumentation problems and
maintenance
22Source: US FDA Guidelines & Presentations
GLP expectations in Bioanalytical….
• Written procedures – establish a priori acceptance/rejection
criteria
– calibration standards, QCs, system suitability assessments
• e.g., at least 67% of all QCs in the batch, and at least 50% of the
QC replicates at each level, must be within 15% of intended
concentrations to accept a run
– chromatography acceptance
• define procedures for automatic and manual integrations,
handling interferences at the retention time of the analyte
– repeat analysis
• define basis for identifying samples for repeat analysis and
reporting the results of repeated samples
23
For Best BE Results
• Effectively incorporate both GCP and GLP
• Follow the relevant regulations & guidelines in both areas
• Set up a QMS that follows the principles of total quality with
QA assuring traceability, integrity, accountability and
compliance of documents and standard procedures
• Be very open during internal & external audits and
inspections
• Address all problem areas (both GCP & GLP violations)
• Implement CAPA and improve systems
24
Concluding Remarks
• Whether claimed or not, GLP compliance of bioanalytical and
clinical chemistry methods can help generate accurate and
precise data for BE studies
• Not all regulatory jurisdictions want it as a mandatory practice
• Many other authoritative regulations etc. (e.g., guidelines,
21CFR 32.9...) mirror the GLP expectations in essence
• Details of GLP expectations are a combination of GLP principles
and bioanalytical guidelines – if both are upheld, you will have
a first class BE data
• Ultimate common goal: integrity, accuracy and quality of
data
25
Thank You Very Much
26

Mais conteúdo relacionado

Mais procurados

Bioanalytical method validation - Global regulatory chalenges
Bioanalytical method validation - Global regulatory chalengesBioanalytical method validation - Global regulatory chalenges
Bioanalytical method validation - Global regulatory chalengesPeter van Amsterdam
 
21 CFR Part 58 & Data integrity
21 CFR Part 58 & Data integrity21 CFR Part 58 & Data integrity
21 CFR Part 58 & Data integrityAnand Pandya
 
System suitability testing
System suitability testingSystem suitability testing
System suitability testingVrushali Tambe
 
Good Automated Manufacturing Practices
Good Automated Manufacturing PracticesGood Automated Manufacturing Practices
Good Automated Manufacturing PracticesPrashant Tomar
 
Good laboratory practices GLP
Good laboratory practices GLPGood laboratory practices GLP
Good laboratory practices GLPkanhaiya kumawat
 
Stability studies of drug ICH Q1
Stability studies of drug ICH Q1 Stability studies of drug ICH Q1
Stability studies of drug ICH Q1 Manali Parab
 
OUT OF SPECIFICATIONS (OOS).pptx
OUT OF SPECIFICATIONS (OOS).pptxOUT OF SPECIFICATIONS (OOS).pptx
OUT OF SPECIFICATIONS (OOS).pptxMohamed Fazil M
 
Out of specification shravan
Out of specification shravanOut of specification shravan
Out of specification shravanshravan dubey
 
Pharma data integrity
Pharma data integrityPharma data integrity
Pharma data integrityGirish Swami
 
Gdp alcoa-160229041605-converted
Gdp alcoa-160229041605-convertedGdp alcoa-160229041605-converted
Gdp alcoa-160229041605-convertedPhaneendrareddy9
 
Data integrity in Pharmaceutical industry
Data integrity in Pharmaceutical industry Data integrity in Pharmaceutical industry
Data integrity in Pharmaceutical industry GxPProfessional
 
Presentation on data integrity in Pharmaceutical Industry
Presentation on data integrity in Pharmaceutical IndustryPresentation on data integrity in Pharmaceutical Industry
Presentation on data integrity in Pharmaceutical IndustrySathish Vemula
 

Mais procurados (20)

Bioanalytical method validation - Global regulatory chalenges
Bioanalytical method validation - Global regulatory chalengesBioanalytical method validation - Global regulatory chalenges
Bioanalytical method validation - Global regulatory chalenges
 
21 CFR Part 58 & Data integrity
21 CFR Part 58 & Data integrity21 CFR Part 58 & Data integrity
21 CFR Part 58 & Data integrity
 
Presentation on US FDA Data Integrity Guidance.
Presentation on US FDA  Data Integrity Guidance.Presentation on US FDA  Data Integrity Guidance.
Presentation on US FDA Data Integrity Guidance.
 
CGMP guidelines
CGMP guidelinesCGMP guidelines
CGMP guidelines
 
System suitability testing
System suitability testingSystem suitability testing
System suitability testing
 
Case study on Out of Specification (OOS).
Case study on Out of Specification (OOS).Case study on Out of Specification (OOS).
Case study on Out of Specification (OOS).
 
ICH- Q3 Impurity
ICH- Q3 ImpurityICH- Q3 Impurity
ICH- Q3 Impurity
 
Good Automated Manufacturing Practices
Good Automated Manufacturing PracticesGood Automated Manufacturing Practices
Good Automated Manufacturing Practices
 
Good laboratory practices GLP
Good laboratory practices GLPGood laboratory practices GLP
Good laboratory practices GLP
 
Glp seminar
Glp  seminarGlp  seminar
Glp seminar
 
Good Documentation Practices
Good Documentation PracticesGood Documentation Practices
Good Documentation Practices
 
Stability studies of drug ICH Q1
Stability studies of drug ICH Q1 Stability studies of drug ICH Q1
Stability studies of drug ICH Q1
 
OUT OF SPECIFICATIONS (OOS).pptx
OUT OF SPECIFICATIONS (OOS).pptxOUT OF SPECIFICATIONS (OOS).pptx
OUT OF SPECIFICATIONS (OOS).pptx
 
Out of specification shravan
Out of specification shravanOut of specification shravan
Out of specification shravan
 
Pharma data integrity
Pharma data integrityPharma data integrity
Pharma data integrity
 
Gdp alcoa-160229041605-converted
Gdp alcoa-160229041605-convertedGdp alcoa-160229041605-converted
Gdp alcoa-160229041605-converted
 
Glp ppt
Glp pptGlp ppt
Glp ppt
 
Computer system validations
Computer system validationsComputer system validations
Computer system validations
 
Data integrity in Pharmaceutical industry
Data integrity in Pharmaceutical industry Data integrity in Pharmaceutical industry
Data integrity in Pharmaceutical industry
 
Presentation on data integrity in Pharmaceutical Industry
Presentation on data integrity in Pharmaceutical IndustryPresentation on data integrity in Pharmaceutical Industry
Presentation on data integrity in Pharmaceutical Industry
 

Destaque

Good Laboratory Practice
Good Laboratory PracticeGood Laboratory Practice
Good Laboratory Practicekaushiktheone
 
Good laboratory practices
Good laboratory practicesGood laboratory practices
Good laboratory practicesSyeda Abeer
 
Good Laboratory Practices ppt
Good Laboratory Practices pptGood Laboratory Practices ppt
Good Laboratory Practices pptKrushna Yadav D K
 
Importance of guidelines in regulatory toxicity testing
Importance of guidelines in regulatory toxicity testingImportance of guidelines in regulatory toxicity testing
Importance of guidelines in regulatory toxicity testingChander K Negi
 
First Step in QbD - How to Get it Right
First Step in QbD - How to Get it RightFirst Step in QbD - How to Get it Right
First Step in QbD - How to Get it RightSun Kim
 
16Planning to protect and preserve health at work while handling chemicals in...
16Planning to protect and preserve health at work while handling chemicals in...16Planning to protect and preserve health at work while handling chemicals in...
16Planning to protect and preserve health at work while handling chemicals in...ohscmcvellore
 
cGMP University - GMP training and Proactive Quality Management | Compliance ...
cGMP University - GMP training and Proactive Quality Management | Compliance ...cGMP University - GMP training and Proactive Quality Management | Compliance ...
cGMP University - GMP training and Proactive Quality Management | Compliance ...David Muchemu
 
Essentials of the trial master file for pharmaceutical
Essentials of the trial master file for pharmaceuticalEssentials of the trial master file for pharmaceutical
Essentials of the trial master file for pharmaceuticalcomplianceonline123
 
Quality Management Systems in Radiotherapy based on ISO 9001 standard
Quality Management Systems in Radiotherapy based on ISO 9001 standardQuality Management Systems in Radiotherapy based on ISO 9001 standard
Quality Management Systems in Radiotherapy based on ISO 9001 standardVal Antoff
 
Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Aakashdeep Raval
 
Schedule Review PMI
Schedule Review PMISchedule Review PMI
Schedule Review PMIChris Carson
 
bioavailability & bioequivalence
bioavailability & bioequivalence bioavailability & bioequivalence
bioavailability & bioequivalence BINDIYA PATEL
 
Pe 6421 chapter 3 iso 9000 quality system oct 13 2014
Pe 6421 chapter 3  iso 9000 quality system oct 13  2014Pe 6421 chapter 3  iso 9000 quality system oct 13  2014
Pe 6421 chapter 3 iso 9000 quality system oct 13 2014Charlton Inao
 

Destaque (20)

Good Laboratory Practice
Good Laboratory PracticeGood Laboratory Practice
Good Laboratory Practice
 
Good laboratory practices
Good laboratory practicesGood laboratory practices
Good laboratory practices
 
Good Laboratory Practices ppt
Good Laboratory Practices pptGood Laboratory Practices ppt
Good Laboratory Practices ppt
 
Glp & quality assurance
Glp & quality assuranceGlp & quality assurance
Glp & quality assurance
 
Qa and glp
Qa and glpQa and glp
Qa and glp
 
Lec05 glp 2007
Lec05 glp 2007Lec05 glp 2007
Lec05 glp 2007
 
Importance of guidelines in regulatory toxicity testing
Importance of guidelines in regulatory toxicity testingImportance of guidelines in regulatory toxicity testing
Importance of guidelines in regulatory toxicity testing
 
First Step in QbD - How to Get it Right
First Step in QbD - How to Get it RightFirst Step in QbD - How to Get it Right
First Step in QbD - How to Get it Right
 
16Planning to protect and preserve health at work while handling chemicals in...
16Planning to protect and preserve health at work while handling chemicals in...16Planning to protect and preserve health at work while handling chemicals in...
16Planning to protect and preserve health at work while handling chemicals in...
 
cGMP University - GMP training and Proactive Quality Management | Compliance ...
cGMP University - GMP training and Proactive Quality Management | Compliance ...cGMP University - GMP training and Proactive Quality Management | Compliance ...
cGMP University - GMP training and Proactive Quality Management | Compliance ...
 
Essentials of the trial master file for pharmaceutical
Essentials of the trial master file for pharmaceuticalEssentials of the trial master file for pharmaceutical
Essentials of the trial master file for pharmaceutical
 
Thesis Defense Presentation
Thesis Defense PresentationThesis Defense Presentation
Thesis Defense Presentation
 
About ISO
About ISOAbout ISO
About ISO
 
Quality Management Systems in Radiotherapy based on ISO 9001 standard
Quality Management Systems in Radiotherapy based on ISO 9001 standardQuality Management Systems in Radiotherapy based on ISO 9001 standard
Quality Management Systems in Radiotherapy based on ISO 9001 standard
 
Gcp 2013
Gcp 2013Gcp 2013
Gcp 2013
 
Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.
 
Schedule Review PMI
Schedule Review PMISchedule Review PMI
Schedule Review PMI
 
bioavailability & bioequivalence
bioavailability & bioequivalence bioavailability & bioequivalence
bioavailability & bioequivalence
 
Pe 6421 chapter 3 iso 9000 quality system oct 13 2014
Pe 6421 chapter 3  iso 9000 quality system oct 13  2014Pe 6421 chapter 3  iso 9000 quality system oct 13  2014
Pe 6421 chapter 3 iso 9000 quality system oct 13 2014
 
Ich gcp
Ich gcpIch gcp
Ich gcp
 

Semelhante a GLP in Bioequivalence Studies

Good Laboratory Practices Pharmaceutical Quality Assurance
Good Laboratory Practices Pharmaceutical Quality AssuranceGood Laboratory Practices Pharmaceutical Quality Assurance
Good Laboratory Practices Pharmaceutical Quality AssuranceShrikantKavitake1
 
GLP in Pharmaceutical Industry by Dr.A S Charan
GLP in Pharmaceutical Industry by Dr.A S CharanGLP in Pharmaceutical Industry by Dr.A S Charan
GLP in Pharmaceutical Industry by Dr.A S CharanCharan Archakam
 
Gcp,glp,gclp presentation
Gcp,glp,gclp presentationGcp,glp,gclp presentation
Gcp,glp,gclp presentationSsuna Bashir
 
GLP-CONCEPT.ppt
GLP-CONCEPT.pptGLP-CONCEPT.ppt
GLP-CONCEPT.pptiamviksin
 
good laboratory practices
good laboratory practicesgood laboratory practices
good laboratory practicesrasika walunj
 
good laboratory practices
good laboratory practices good laboratory practices
good laboratory practices rasika walunj
 
Good laboratory practices
Good laboratory practicesGood laboratory practices
Good laboratory practicessuraj p rajan
 
Quality management systems: Good Laboratory Practice (QMS GLP)
Quality management systems: Good Laboratory Practice (QMS GLP)Quality management systems: Good Laboratory Practice (QMS GLP)
Quality management systems: Good Laboratory Practice (QMS GLP)Dr Ajay Kumar Tiwari
 
GOOD LABORATORY PRACTICE by ILyas Mphil student.pptx
GOOD LABORATORY PRACTICE by ILyas Mphil student.pptxGOOD LABORATORY PRACTICE by ILyas Mphil student.pptx
GOOD LABORATORY PRACTICE by ILyas Mphil student.pptxAtaUrRahman50751
 
Good Laboratory Practices (GLP) and USP 1058 Validation.pdf
Good Laboratory Practices (GLP) and USP 1058 Validation.pdfGood Laboratory Practices (GLP) and USP 1058 Validation.pdf
Good Laboratory Practices (GLP) and USP 1058 Validation.pdfConference Panel
 
QMS Seminar.pptx
QMS Seminar.pptxQMS Seminar.pptx
QMS Seminar.pptxRohitKoli29
 
Quality management systems: Good Laboratory Practice (QMS GLP)
Quality management systems: Good Laboratory Practice (QMS GLP)Quality management systems: Good Laboratory Practice (QMS GLP)
Quality management systems: Good Laboratory Practice (QMS GLP)Dr Ajay Kumar Tiwari
 

Semelhante a GLP in Bioequivalence Studies (20)

Good Laboratory Practices Pharmaceutical Quality Assurance
Good Laboratory Practices Pharmaceutical Quality AssuranceGood Laboratory Practices Pharmaceutical Quality Assurance
Good Laboratory Practices Pharmaceutical Quality Assurance
 
GLP.pdf
GLP.pdfGLP.pdf
GLP.pdf
 
GLP FINAL.pptx
GLP FINAL.pptxGLP FINAL.pptx
GLP FINAL.pptx
 
GLP in Pharmaceutical Industry by Dr.A S Charan
GLP in Pharmaceutical Industry by Dr.A S CharanGLP in Pharmaceutical Industry by Dr.A S Charan
GLP in Pharmaceutical Industry by Dr.A S Charan
 
Gcp,glp,gclp presentation
Gcp,glp,gclp presentationGcp,glp,gclp presentation
Gcp,glp,gclp presentation
 
GLP.pptx
GLP.pptxGLP.pptx
GLP.pptx
 
GLP-CONCEPT.ppt
GLP-CONCEPT.pptGLP-CONCEPT.ppt
GLP-CONCEPT.ppt
 
good laboratory practices
good laboratory practicesgood laboratory practices
good laboratory practices
 
GLP
GLPGLP
GLP
 
good laboratory practices
good laboratory practices good laboratory practices
good laboratory practices
 
Good laboratory practice
Good laboratory practiceGood laboratory practice
Good laboratory practice
 
Good laboratory practices
Good laboratory practicesGood laboratory practices
Good laboratory practices
 
Good lab practices (GLP)
Good lab practices (GLP)Good lab practices (GLP)
Good lab practices (GLP)
 
Quality control and quality assurance
Quality control and quality assuranceQuality control and quality assurance
Quality control and quality assurance
 
Good laboratory practices
Good laboratory practicesGood laboratory practices
Good laboratory practices
 
Quality management systems: Good Laboratory Practice (QMS GLP)
Quality management systems: Good Laboratory Practice (QMS GLP)Quality management systems: Good Laboratory Practice (QMS GLP)
Quality management systems: Good Laboratory Practice (QMS GLP)
 
GOOD LABORATORY PRACTICE by ILyas Mphil student.pptx
GOOD LABORATORY PRACTICE by ILyas Mphil student.pptxGOOD LABORATORY PRACTICE by ILyas Mphil student.pptx
GOOD LABORATORY PRACTICE by ILyas Mphil student.pptx
 
Good Laboratory Practices (GLP) and USP 1058 Validation.pdf
Good Laboratory Practices (GLP) and USP 1058 Validation.pdfGood Laboratory Practices (GLP) and USP 1058 Validation.pdf
Good Laboratory Practices (GLP) and USP 1058 Validation.pdf
 
QMS Seminar.pptx
QMS Seminar.pptxQMS Seminar.pptx
QMS Seminar.pptx
 
Quality management systems: Good Laboratory Practice (QMS GLP)
Quality management systems: Good Laboratory Practice (QMS GLP)Quality management systems: Good Laboratory Practice (QMS GLP)
Quality management systems: Good Laboratory Practice (QMS GLP)
 

Mais de Bhaswat Chakraborty

Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...
Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...
Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...Bhaswat Chakraborty
 
Statistical outliers in BE Studies DIA 12 april 2019
Statistical outliers in BE Studies DIA 12 april 2019Statistical outliers in BE Studies DIA 12 april 2019
Statistical outliers in BE Studies DIA 12 april 2019Bhaswat Chakraborty
 
Respiratory studies right approach in designs dia 11 april 2019 r
Respiratory studies right approach  in designs dia 11 april 2019 rRespiratory studies right approach  in designs dia 11 april 2019 r
Respiratory studies right approach in designs dia 11 april 2019 rBhaswat Chakraborty
 
Simplifying study designs and statistical models for new dose & dosage forms ...
Simplifying study designs and statistical models for new dose & dosage forms ...Simplifying study designs and statistical models for new dose & dosage forms ...
Simplifying study designs and statistical models for new dose & dosage forms ...Bhaswat Chakraborty
 
Equivalence approches for complex generics DIA 11 april 2019
Equivalence approches for complex generics DIA 11 april 2019 Equivalence approches for complex generics DIA 11 april 2019
Equivalence approches for complex generics DIA 11 april 2019 Bhaswat Chakraborty
 
Clinical Trial Requirements Medical Devices 27 dec2018
Clinical Trial Requirements Medical Devices 27 dec2018Clinical Trial Requirements Medical Devices 27 dec2018
Clinical Trial Requirements Medical Devices 27 dec2018Bhaswat Chakraborty
 
Writing scientific papers FINALDec 2018
Writing scientific papers FINALDec 2018Writing scientific papers FINALDec 2018
Writing scientific papers FINALDec 2018Bhaswat Chakraborty
 
Multidisc review of NDAs and BLAs nipicon 2018 Dr. Chakraborty
Multidisc review of NDAs and BLAs nipicon 2018 Dr. ChakrabortyMultidisc review of NDAs and BLAs nipicon 2018 Dr. Chakraborty
Multidisc review of NDAs and BLAs nipicon 2018 Dr. ChakrabortyBhaswat Chakraborty
 
Teaching by stories, anecdotes and historical facts sept 25 2018
Teaching by stories, anecdotes and historical facts sept 25 2018Teaching by stories, anecdotes and historical facts sept 25 2018
Teaching by stories, anecdotes and historical facts sept 25 2018Bhaswat Chakraborty
 
Orientation and Adaptation for Post-Graduate Pharmacy Programs
Orientation and Adaptation for Post-Graduate Pharmacy ProgramsOrientation and Adaptation for Post-Graduate Pharmacy Programs
Orientation and Adaptation for Post-Graduate Pharmacy ProgramsBhaswat Chakraborty
 
Plagiarism and Techniques to Avoid Plagiarism
Plagiarism and Techniques to Avoid PlagiarismPlagiarism and Techniques to Avoid Plagiarism
Plagiarism and Techniques to Avoid PlagiarismBhaswat Chakraborty
 
Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...
Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...
Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...Bhaswat Chakraborty
 
Pharmacists in Drug Discovery & Development
Pharmacists in Drug Discovery & Development Pharmacists in Drug Discovery & Development
Pharmacists in Drug Discovery & Development Bhaswat Chakraborty
 
Clinical Development of Biosimilars
Clinical Development of Biosimilars Clinical Development of Biosimilars
Clinical Development of Biosimilars Bhaswat Chakraborty
 
Challenges in Phase III Cancer Clinical Trials
Challenges in Phase III Cancer Clinical Trials Challenges in Phase III Cancer Clinical Trials
Challenges in Phase III Cancer Clinical Trials Bhaswat Chakraborty
 
Bioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug ProductsBioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug ProductsBhaswat Chakraborty
 
Bioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug ProductsBioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug ProductsBhaswat Chakraborty
 
Protein binding of drugs and screening of drugs by physicochemical properties
Protein binding of drugs  and screening of drugs by physicochemical propertiesProtein binding of drugs  and screening of drugs by physicochemical properties
Protein binding of drugs and screening of drugs by physicochemical propertiesBhaswat Chakraborty
 
Developing Protocols & Procedures for CT Data Integrity
Developing Protocols & Procedures for CT Data Integrity Developing Protocols & Procedures for CT Data Integrity
Developing Protocols & Procedures for CT Data Integrity Bhaswat Chakraborty
 

Mais de Bhaswat Chakraborty (20)

Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...
Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...
Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...
 
Statistical outliers in BE Studies DIA 12 april 2019
Statistical outliers in BE Studies DIA 12 april 2019Statistical outliers in BE Studies DIA 12 april 2019
Statistical outliers in BE Studies DIA 12 april 2019
 
Respiratory studies right approach in designs dia 11 april 2019 r
Respiratory studies right approach  in designs dia 11 april 2019 rRespiratory studies right approach  in designs dia 11 april 2019 r
Respiratory studies right approach in designs dia 11 april 2019 r
 
Simplifying study designs and statistical models for new dose & dosage forms ...
Simplifying study designs and statistical models for new dose & dosage forms ...Simplifying study designs and statistical models for new dose & dosage forms ...
Simplifying study designs and statistical models for new dose & dosage forms ...
 
Equivalence approches for complex generics DIA 11 april 2019
Equivalence approches for complex generics DIA 11 april 2019 Equivalence approches for complex generics DIA 11 april 2019
Equivalence approches for complex generics DIA 11 april 2019
 
Clinical Trial Requirements Medical Devices 27 dec2018
Clinical Trial Requirements Medical Devices 27 dec2018Clinical Trial Requirements Medical Devices 27 dec2018
Clinical Trial Requirements Medical Devices 27 dec2018
 
Writing scientific papers FINALDec 2018
Writing scientific papers FINALDec 2018Writing scientific papers FINALDec 2018
Writing scientific papers FINALDec 2018
 
Multidisc review of NDAs and BLAs nipicon 2018 Dr. Chakraborty
Multidisc review of NDAs and BLAs nipicon 2018 Dr. ChakrabortyMultidisc review of NDAs and BLAs nipicon 2018 Dr. Chakraborty
Multidisc review of NDAs and BLAs nipicon 2018 Dr. Chakraborty
 
Teaching by stories, anecdotes and historical facts sept 25 2018
Teaching by stories, anecdotes and historical facts sept 25 2018Teaching by stories, anecdotes and historical facts sept 25 2018
Teaching by stories, anecdotes and historical facts sept 25 2018
 
Orientation and Adaptation for Post-Graduate Pharmacy Programs
Orientation and Adaptation for Post-Graduate Pharmacy ProgramsOrientation and Adaptation for Post-Graduate Pharmacy Programs
Orientation and Adaptation for Post-Graduate Pharmacy Programs
 
Plagiarism and Techniques to Avoid Plagiarism
Plagiarism and Techniques to Avoid PlagiarismPlagiarism and Techniques to Avoid Plagiarism
Plagiarism and Techniques to Avoid Plagiarism
 
Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...
Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...
Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...
 
Ethics in Pharmacy
Ethics in Pharmacy Ethics in Pharmacy
Ethics in Pharmacy
 
Pharmacists in Drug Discovery & Development
Pharmacists in Drug Discovery & Development Pharmacists in Drug Discovery & Development
Pharmacists in Drug Discovery & Development
 
Clinical Development of Biosimilars
Clinical Development of Biosimilars Clinical Development of Biosimilars
Clinical Development of Biosimilars
 
Challenges in Phase III Cancer Clinical Trials
Challenges in Phase III Cancer Clinical Trials Challenges in Phase III Cancer Clinical Trials
Challenges in Phase III Cancer Clinical Trials
 
Bioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug ProductsBioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug Products
 
Bioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug ProductsBioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug Products
 
Protein binding of drugs and screening of drugs by physicochemical properties
Protein binding of drugs  and screening of drugs by physicochemical propertiesProtein binding of drugs  and screening of drugs by physicochemical properties
Protein binding of drugs and screening of drugs by physicochemical properties
 
Developing Protocols & Procedures for CT Data Integrity
Developing Protocols & Procedures for CT Data Integrity Developing Protocols & Procedures for CT Data Integrity
Developing Protocols & Procedures for CT Data Integrity
 

Último

CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 

Último (20)

CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 

GLP in Bioequivalence Studies

  • 1. Role of GLP Compliance in Generating Accurate & Reproducible BE Data Dr. Bhaswat S. Chakraborty Sr. VP & Chair, R&D Core Committee Cadila Pharmaceuticals Ltd. Presented at ACRO India Workshop AMA, Ahmedabad, India, July 19-20, 2013 1
  • 2. Contents • GLP, its evolution • Fundamentals of GLP – Resources – Rules & Characterization – Documentation & QAU • Regulatory BE studies • GLP in BE – USFDA, EU • Legal & Excellence GLP • GLP expectations in Bioanalytical • Best BE Results • Concluding remarks 2
  • 3. Good Laboratory Practices (GLP) • Good Laboratory Practices or GLPs were initially invoked in a reaction to malpractices in laboratories conducting safety experiments of medicines. • In early 1970s, research laboratories in the USA were found doing work in unethical ways, like: – data generation without conduct of study – falsification of laboratory work – replacement of dead animals and fabrication of test results etc. • As a result, a series of guidelines were issued by US FDA, Japan and finally by the whole group of OECD countries. Board and Dent 19963
  • 4. Evolution of GLP • 1976 – USA: FDA proposals • 1978 – USA: FDA final rules • 1980 – USA : FDA amendment to GLP • 1981 – OECD: Guidelines for testing of chemicals – OECD Paris and Guidelines for National GLP inspections – Paris • 1982 – OECD: GLP in testing of chemicals - Paris • 1984 – Japan: GLP proposals and notification to agricultural production bureau • 1987 – USA: FDA amendment final rule • 1988 – OECD: Final report for working group on mutual recognition of compliance with GLP • 1989 – UK: GLP compliance program Board and Dent 19964
  • 5. Fundamentals of GLP 1) Resources: organization, personnel, facilities and equipment. 2) Rules: protocols and written procedures (SOPs). 3) Characterization: test items and test systems. 4) Documentation: raw data, final report and archives. 5) Quality assurance unit. 5
  • 6. Resources • Organization and Personnel: – structure of the research organization and responsibilities of the research personnel should be clearly defined – staffing levels must be sufficient to perform the tasks required – qualifications and the training of staff must also be defined and documented • Facilities and Equipment: – sufficient facilities and equipment must be existent in order to perform the studies – all equipment must be in working order. 6
  • 7. Rules & Characterization • Protocols and Written Procedures: – main steps of research studies must be described in the study plan or protocol – for repeatability of the studies and reproducibility of results, routine procedures are described in SOPs • Test item and the Test system – essential to know as much as possible about the test item and about the test system (often an animal or plant) to which it is administered. 7
  • 8. Documentation & QAU • Raw data must be accurately captured and organized to reflect the procedures and conditions of the study • Final report is the responsibility of the study director, ensuring – that the contents, results and interpretation thereof are accurate • Archives should be safe for many years and equipped with logical and prompt retrieval.   • Quality assurance (QA) is a team assuring GLP compliance – organized independently of the operational and study program, and function as witnesses to the whole pre-clinical research process. 8
  • 9. Critical GLP Violations • Fabrication or falsification of data • No Quality Assurance • No study allotment • No approved written study plans • Failure to date, initial or sign data entries • No training records and / or no job descriptions for study personnel • Absence of required information in final reports 9
  • 10. Critical GCP Violations • Fabrication or falsification of data • Evidence that formal procedure/systems were not in place or rather weak • Lack of/inadequate Quality Certification. • Importation and mfg. of investigational product without regulatory licence • Inaccurate information about investigational product is supplied to regulatory agency • Use of expired/recalled/non GMP manufactured investigational product • Poor/ineffective blinding system • Poor accountability of investigational product • Poorly documented/incorrect sponsorship/Legal Representative arrangements • Uncontrolled site to site transfer • Failure to observe IND conditions • Failure to report serious breaches of trial protocol/GCP • Little or no oversight of pharmacovigilance requirements
  • 11. Regulatory Bioequivalence (BE) Studies • Clinical studies in healthy volunteers – GCP compliance is a must • Involves laboratory measurements of drug concentrations in blood samples – Logically GLP should be applicable • They are not non-clinical, safety studies – Thus may NOT have to CLAIM GLP compliance 11
  • 12. Scope Demarcation: GCP and GLP • GCP: relate to clinical studies using human volunteers patients and also relate to most of the clinical procedures that can be carried out without a laboratory test – Includes all clinical phase I-IV studies • GLP apply to all analytical and testing process all safety studies for human health market approval and include QC assays, clinical chemistry and tests by instruments and certain bioanalytical procedures – Excludes validation studies, cosmetic safety, bioanalytical for efficacy studies including animal efficacy studies • Good QA is applicable to all biomedical research practices 12
  • 13. GLP in BE • Common perceptions – Confusing – Only in the testing of non-clinical safety aspects – Applies to bioanalytical? Or bioanalytical only? – Wherever there is a lab • Clinical pathology • Serology • Microbiology • Bioanalytical… 13
  • 14. Guidance for Industry, USFDA/CDER, May 2001 • “The analytical laboratory conducting pharmacology/toxicology and other preclinical studies for regulatory submissions should adhere to FDA’s Good Laboratory Practices (GLPs) (21 CFR part 58) and to sound principles of quality assurance throughout the testing process. • The bioanalytical method for human BA, BE, PK, and drug interaction studies must meet the criteria in 21 CFR 320.29.” 14
  • 15. 21 CFR 320.29 • “….shall be demonstrated to be accurate and of sufficient sensitivity to measure, with appropriate precision, the actual concentration of the active drug ingredient or therapeutic moiety, or its active metabolite(s), achieved in the body. ……” 15
  • 16. EMEA CPMP/EWP/QWP/1401/98 • “The bioanalytical part of bioequivalence trials should be performed in accordance with the principles of Good Laboratory Practice (GLP). • However, as human bioanalytical studies fall outside the scope of GLP, the sites conducting the studies are not required to be monitored as part of a national GLP compliance programme.” 16
  • 17. Bioanalytical Guidelines EMEA/CHMP/EWP/192217/2009 • “The validation of bioanalytical methods and the analysis of study samples should be performed in accordance with the principles of Good Laboratory Practice (GLP). • However, as human bioanalytical studies fall outside of the scope of GLP, as defined in Directive 2004/10/EC, the sites conducting the human studies are not required to be monitored as part of a national GLP compliance programme. • In addition, for clinical trials in humans the principles of Good Clinical Practice (GCP) should be followed”. 17
  • 18. 18
  • 19. Excellence vs Legal GLP • Legal GLP – Accredited – Monitored & certified by authorities • Excellence in GLP – Protocol & study director – Proper sample collection, storage and processing – Validated calibration and QC – Successful analysis of batches – High quality data (QC) – Excellent QA • Tracing, accountability & accuracy – Proper reporting 19
  • 20. GLP expectations in Bioanalytical • Pre-study method validation – precision and accuracy – intra- and inter-batch across calibration range, including LOQ – selectivity – test for endogenous/exogenous interferences – stability under study conditions – freeze/thaw, long-term frozen storage, bench-top, auto-sampler (extract), stock solution – recommend freshly prepared samples for comparison – consider conditions of actual use – for example, increased batch size during actual use • Written, thorough documentation of the bioanalytical method and results of validation 20Source: US FDA Guidelines & Presentations
  • 21. GLP expectations in Bioanalytical.. • During incurred sample analysis – select calibration range and QCs based on expected concentrations for the study – include a standard curve and quality control samples with each batch of subject samples – assure consistent integration of all chromatograms within a batch • prepare complete study reports tabulate results for calibration standards, QCs, subject samples • list repeat results and the reason for the repeat • list deviations and their impact • description of failed runs 21Source: US FDA Guidelines & Presentations
  • 22. GLP expectations in Bioanalytical... • Reference standard – record identity, purity, expiration date, lot number • Document preparation – of stock solutions, and matrix- based calibration standards and quality control (QC) samples • Sample handling – store study samples under conditions that maintain their integrity • Document – storage condition, freezer removal/return • Equipment – record instrumentation problems and maintenance 22Source: US FDA Guidelines & Presentations
  • 23. GLP expectations in Bioanalytical…. • Written procedures – establish a priori acceptance/rejection criteria – calibration standards, QCs, system suitability assessments • e.g., at least 67% of all QCs in the batch, and at least 50% of the QC replicates at each level, must be within 15% of intended concentrations to accept a run – chromatography acceptance • define procedures for automatic and manual integrations, handling interferences at the retention time of the analyte – repeat analysis • define basis for identifying samples for repeat analysis and reporting the results of repeated samples 23
  • 24. For Best BE Results • Effectively incorporate both GCP and GLP • Follow the relevant regulations & guidelines in both areas • Set up a QMS that follows the principles of total quality with QA assuring traceability, integrity, accountability and compliance of documents and standard procedures • Be very open during internal & external audits and inspections • Address all problem areas (both GCP & GLP violations) • Implement CAPA and improve systems 24
  • 25. Concluding Remarks • Whether claimed or not, GLP compliance of bioanalytical and clinical chemistry methods can help generate accurate and precise data for BE studies • Not all regulatory jurisdictions want it as a mandatory practice • Many other authoritative regulations etc. (e.g., guidelines, 21CFR 32.9...) mirror the GLP expectations in essence • Details of GLP expectations are a combination of GLP principles and bioanalytical guidelines – if both are upheld, you will have a first class BE data • Ultimate common goal: integrity, accuracy and quality of data 25
  • 26. Thank You Very Much 26